Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

3V0V

Fab WN1 222-5 unliganded

3V0V の概要
エントリーDOI10.2210/pdb3v0v/pdb
関連するPDBエントリー3V0W
分子名称WN1 222-5 Fab (IgG2a) light chain, WN1 222-5 Fab (IgG2a) heavy chain (3 entities in total)
機能のキーワードbeta sheets, antibody, fab, immune system
由来する生物種Mus musculus
詳細
タンパク質・核酸の鎖数4
化学式量合計93616.17
構造登録者
Gomery, K.,Evans, S.V. (登録日: 2011-12-08, 公開日: 2012-12-05, 最終更新日: 2024-10-16)
主引用文献Gomery, K.,Muller-Loennies, S.,Brooks, C.L.,Brade, L.,Kosma, P.,Di Padova, F.,Brade, H.,Evans, S.V.
Antibody WN1 222-5 mimics Toll-like receptor 4 binding in the recognition of LPS.
Proc.Natl.Acad.Sci.USA, 109:20877-20882, 2012
Cited by
PubMed Abstract: Escherichia coli infections, a leading cause of septic shock, remain a major threat to human health because of the fatal action to endotoxin (LPS). Therapeutic attempts to neutralize endotoxin currently focus on inhibiting the interaction of the toxic component lipid A with myeloid differentiating factor 2, which forms a trimeric complex together with Toll-like receptor 4 to induce immune cell activation. The 1.73-Å resolution structure of the unique endotoxin-neutralizing protective antibody WN1 222-5 in complex with the core region shows that it recognizes LPS of all E. coli serovars in a manner similar to Toll-like receptor 4, revealing that protection can be achieved by targeting the inner core of LPS and that recognition of lipid A is not required. Such interference with Toll-like receptor complex formation opens new paths for antibody sepsis therapy independent of lipid A antagonists.
PubMed: 23184990
DOI: 10.1073/pnas.1209253109
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.13 Å)
構造検証レポート
Validation report summary of 3v0v
検証レポート(詳細版)ダウンロードをダウンロード

252456

件を2026-04-22に公開中

PDB statisticsPDBj update infoContact PDBjnumon